NCT00543972 2009-05-14Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid LeukemiaSanofiPhase 1 Terminated12 enrolled